Vis enkel innførsel

dc.contributor.authorJahagirdar, Deepa
dc.contributor.authorWalters, Magdalene K
dc.contributor.authorNovotney, Amanda
dc.contributor.authorBrewer, Edmond D
dc.contributor.authorFrank, Tahvi D
dc.contributor.authorKisa, Adnan
dc.contributor.authorCarter, Austin
dc.contributor.authorBiehl, Molly H.
dc.contributor.authorHay, Simon I.
dc.contributor.authorKisa, Sezer
dc.contributor.authorMurray, Christopher J L
dc.contributor.authorKyu, Hmwe H.
dc.contributor.authorHIV Collaborators, GBD 2019
dc.date.accessioned2022-01-20T11:58:31Z
dc.date.available2022-01-20T11:58:31Z
dc.date.created2021-09-28T13:50:18Z
dc.date.issued2021-09-27
dc.identifier.citationThe Lancet HIV. 2021, .en_US
dc.identifier.issn2405-4704
dc.identifier.issn2352-3018
dc.identifier.urihttps://hdl.handle.net/11250/2838463
dc.description.abstractBackground: The sustainable development goals (SDGs) aim to end HIV/AIDS as a public health threat by 2030. Understanding the current state of the HIV epidemic and its change over time is essential to this effort. This study assesses the current sex-specific HIV burden in 204 countries and territories and measures progress in the control of the epidemic. Methods: To estimate age-specific and sex-specific trends in 48 of 204 countries, we extended the Estimation and Projection Package Age-Sex Model to also implement the spectrum paediatric model. We used this model in cases where age and sex specific HIV-seroprevalence surveys and antenatal care-clinic sentinel surveillance data were available. For the remaining 156 of 204 locations, we developed a cohort-incidence bias adjustment to derive incidence as a function of cause-of-death data from vital registration systems. The incidence was input to a custom Spectrum model. To assess progress, we measured the percentage change in incident cases and deaths between 2010 and 2019 (threshold >75% decline), the ratio of incident cases to number of people living with HIV (incidence-to-prevalence ratio threshold <0·03), and the ratio of incident cases to deaths (incidence-to-mortality ratio threshold <1·0). Findings: In 2019, there were 36·8 million (95% uncertainty interval [UI] 35·1–38·9) people living with HIV worldwide. There were 0·84 males (95% UI 0·78–0·91) per female living with HIV in 2019, 0·99 male infections (0·91–1·10) for every female infection, and 1·02 male deaths (0·95–1·10) per female death. Global progress in incident cases and deaths between 2010 and 2019 was driven by sub-Saharan Africa (with a 28·52% decrease in incident cases, 95% UI 19·58–35·43, and a 39·66% decrease in deaths, 36·49–42·36). Elsewhere, the incidence remained stable or increased, whereas deaths generally decreased. In 2019, the global incidence-to-prevalence ratio was 0·05 (95% UI 0·05–0·06) and the global incidence-to-mortality ratio was 1·94 (1·76–2·12). No regions met suggested thresholds for progress. Interpretation: Sub-Saharan Africa had both the highest HIV burden and the greatest progress between 1990 and 2019. The number of incident cases and deaths in males and females approached parity in 2019, although there remained more females with HIV than males with HIV. Globally, the HIV epidemic is far from the UNAIDS benchmarks on progress metrics.en_US
dc.description.sponsorshipFunding was provided by The Bill & Melinda Gates Foundation, the National Institute of Mental Health of the US National Institutes of Health (NIH), and the National Institute on Aging of the NIH.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.ispartofseriesThe Lancet HIV;Volume 8, Issue 10
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectSex-specific burdensen_US
dc.subjectHIVen_US
dc.subjectDevelopment goalsen_US
dc.subjectEpidemic controlen_US
dc.subjectAIDSen_US
dc.subjectMortalityen_US
dc.titleGlobal, regional, and national sex-specific burden and control of the HIV epidemic, 1990–2019, for 204 countries and territories: the Global Burden of Diseases Study 2019en_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2021 The Author(s).en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doihttps://doi.org/10.1016/S2352-3018(21)00152-1
dc.identifier.cristin1939828
dc.source.journalThe Lancet HIVen_US
dc.source.volume8en_US
dc.source.issue10en_US
dc.source.pagenumber633-651en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal